# About Biotide Peptides — An Independent GH-Axis Research Desk > About Biotide Peptides: an independent literature digest on Growth Hormone Axis research peptides. How it is compiled, and what it is not — not a seller, not a clinic, not medical advice. An independent, citation-anchored digest of the GH-axis research-peptide literature. Not a vendor. Not a clinic. Not medical advice. ## What Biotide Peptides is Biotide Peptides is an independent editorial reference desk covering the published research on three peptides studied for the **Growth Hormone Axis**: CJC-1295 / Ipamorelin (the research combination), CJC-1295 (the GHRH analogue), and Ipamorelin (the selective ghrelin-receptor agonist), with the combination entry as the lead. The desk exists to make an uneven, technically demanding, and frequently overstated literature legible. The GH-axis research space is populated by a small number of pharmacokinetic studies, a larger body of receptor and animal work, a single failed Phase 2 trial, and an enormous volume of community discussion that regularly outpaces the evidence. The goal here is to close that gap — to tell a reader, in plain clinical language and with citations, what each compound was studied for, in which species, with what outcomes, and where the evidence genuinely stops. The organizing lens is the CJC-1295 + ipamorelin stack: how a GHRH analogue and a selective GHRP work together through complementary receptor pathways, why the combination concept is scientifically coherent, and why the combination itself remains untested as a fixed blend in controlled human work. Each compound has its own page; a comparison page lines all three up; and a single shared references list aggregates every source. ## How it is compiled Three principles govern what appears on this site. *First, everything is anchored to the peer-reviewed literature.* Every research claim is tied to a numbered citation — PubMed-indexed journal articles, reviews, and primary pharmacokinetic studies, with DOIs and PubMed links — collected on the [references page](/references). Where a finding comes from a review rather than a primary study, that distinction is flagged. *Second, the evidence is reported at its true strength.* Doses are described in the species and route in which they were studied — for example, "30 micrograms per kilogram subcutaneously in healthy adults" — never scaled to humans or framed as a recommendation. Where evidence is from animal models, single-arm studies, or inferred from a related compound rather than the one under discussion, the text says so explicitly. The known gaps — no fixed-blend combination trial, no long-term human safety data, a failed Phase 2 — are in the body of each page, not buried in a disclaimer. *Third, the three pages are cross-referenced.* Because the stack's rationale runs through both pages, readers following the mechanism from the GHRH arm to the GHS-R1a arm to the combination can do so through in-text links. The [comparison page](/compare) makes the structural differences explicit in one place. ## What it is not Biotide Peptides is not a store, not a clinic, and not a source of medical advice. It does not sell, supply, source, or broker any peptide or research chemical, and it has no affiliate or referral relationship with any vendor. It does not employ clinicians, diagnose conditions, or prescribe anything. It does not recommend a dose, schedule, or route of administration for any person, and it never presents an animal-study or early-human-study dose as something a person should use. The peptides discussed here are research compounds. None is an approved medicine for human use; all three are prohibited in sport under WADA. The compounding status of both CJC-1295 and ipamorelin changed in 2024, with both removed from FDA Category 2 and reviewed at the October 2024 PCAC meeting without a positive compounding recommendation. Readers interested in any condition described in the underlying research should consult a licensed clinician operating within their own jurisdiction, working with regulated, evidence-based options. This desk offers an accurate briefing on what the literature actually says — nothing more, and nothing it pretends to be. --- A peer-reviewed briefing on GH-axis research peptides — citations anchored to primary literature, no products, no clinical recommendations.